Medicare Lab Payment Cuts: Industry Pushback and Policy Implications

Major clinical laboratory companies are intensifying their efforts to halt scheduled Medicare payment cuts for diagnostic tests set to begin in early 2026, raising fundamental questions about reimbursement policy, data accuracy, patient access, and the future sustainability of diagnostic services in the U.S. healthcare system.

Under current law, the Medicare Clinical Laboratory Fee Schedule (CLFS), which governs reimbursement for tests billed under Medicare Part B, is subject to periodic adjustment based on private‑payer market data collected under the Protecting Access to Medicare Act (PAMA) of 2014. Congress passed PAMA to align Medicare payments with the average rates paid by private insurers, on the theory that Medicare was historically overpaying for some tests. However, the implementation of PAMA has generated deep controversy, largely due to flawed data collection and repeated cuts based on non‑representative samples of lab rates.

In late 2025, industry leaders such as Quest Diagnostics and LabCorp mobilized in Washington, urging legislators to delay or override up to a 15 percent reduction in CLFS reimbursement that is currently scheduled to take effect on January 31, 2026, for nearly 800 current procedural terminology (CPT) lab codes. These companies argue that such steep cuts will impede investment in new diagnostic technologies, including innovations in precision medicine and rapid testing, and could threaten patient access to essential lab services.

The Roots of the Dispute: PAMA and Data Collection Challenges

When PAMA went into effect, eligible laboratories were required to report private payor payment rates and test volumes to the Centers for Medicare & Medicaid Services (CMS). CMS then used a weighted median of those data to set new Medicare reimbursement rates under the CLFS. In principle, this approach aimed to create a market‑based rate structure that reflected actual payments across the private sector.

In practice, the first PAMA data collection period — conducted around 2016 — was dominated by responses from large independent labs. Hospital outreach labs, physician office labs, and smaller regional providers were dramatically underrepresented, capturing less than 1 percent of the data despite accounting for a significant share of clinical test utilization. The result was a skewed rate‑setting process that disproportionately reflected the lower costs achieved by high‑volume national labs.

Critics, including industry coalitions and clinical lab associations, argue that this flawed data foundation led to artificially low Medicare reimbursement rates, with deep cuts occurring over multiple years. Early CLFS cuts — which eliminated up to 10 percent reductions per year for several years — resulted in nearly $4 billion in payment reductions in the first three years alone. More cuts on top of those already experienced are expected if 2026 reforms proceed unchanged.

Industry Response and Legislative Action

In response to the looming cuts, a broad coalition of clinical lab stakeholders — including trade associations and professional organizations — is urging Congress to enact long‑term legislative reform rather than temporary relief. One prominent proposal is the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, a bipartisan bill that seeks to overhaul the CLFS rate‑setting process. The RESULTS Act would require the use of more representative commercial market data in setting Medicare lab fees, simplify reporting burdens, and cap future cuts, thereby stabilizing payments and preserving access to essential testing services.

Supporters of RESULTS argue that the current system’s shortcomings — rooted in inadequate data collection and an unreliable rate basis — undermine both clinical innovation and financial viability for labs of all sizes. According to advocacy letters from organizations like the Association for Diagnostics & Laboratory Medicine (ADLM), more representative market data and a predictable fee formula would help protect labs in rural areas and underserved communities that rely on Medicare reimbursement to sustain operations.

Some lawmakers have also supported alternate reforms such as the Saving Access to Laboratory Services Act (SALSA), which would cap annual payment reductions at 5 percent and improve the statistical validity of market rate data used to calculate Medicare reimbursements. While SALSA and similar proposals have garnered endorsements from multiple professional and patient advocacy groups, they have not yet advanced to enactment.

Economic and Clinical Implications for Providers

The significance of these policy debates extends far beyond lab profit margins. Clinical laboratory services account for a critical share of diagnostic decision‑making — informing an estimated 70 percent of all healthcare decisions — yet represent less than 1 percent of total Medicare spending. Because lab work underpins preventive care, chronic disease management, and early detection strategies, large reductions in reimbursement could affect clinicians’ ability to order necessary tests or partner effectively with laboratories to manage patient care.

From a financial standpoint, companies like Quest Diagnostics and LabCorp have publicly noted that unmitigated cuts could each reduce revenue by up to $100 million in 2026. Smaller independent labs, which lack the scale economies of national firms, may face even greater fiscal challenges, potentially leading to service consolidation, reduced geographic coverage, or closures.

For providers, the prospect of lower lab reimbursement rates is not just a back‑office concern; it could influence clinical decision‑making, utilization patterns, and partnerships with testing providers. Physicians and health systems may need to consider alternative arrangements for lab services, renegotiate contracts with laboratories, or develop internal capacity to maintain quality while managing cost pressures. Additionally, disruptions in provider–lab relationships risk fragmenting care coordination, particularly for complex or chronic patients who rely on regular testing.

Policy Tradeoffs and Strategic Considerations

Policy makers face a complex calculus. On one hand, Medicare seeks to control costs and align payments with marketplace realities. On the other, overly steep and poorly calibrated reimbursement cuts risk destabilizing a foundational service line in healthcare. The saga of PAMA implementation highlights the dangers of rate formulas that do not adequately reflect service costs, access requirements, and heterogeneity across clinical settings.

Temporary delays of payment reductions have occurred repeatedly, with Congress postponing cuts five times through short‑term funding bills or carve‑outs. Each delay buys time but does not resolve the underlying structural concerns with data collection and rate calculation methodology.

A sustainable solution would likely involve more robust data sources, better representation across laboratory types, and enhanced statistical methodologies to ensure Medicare reimbursements fairly mirror nationwide market costs — balancing fiscal responsibility with access to essential diagnostic testing. Legislation like RESULTS or SALSA attempts to strike that balance, though cost estimates and long‑term budgetary impacts remain subjects of ongoing analysis.

Political and Healthcare System Dynamics

As Congress reconvenes in 2026, clinical laboratory reimbursement issues are poised to become part of broader healthcare financing debates. With lawmakers juggling priorities such as Medicare physician payment reforms, prescription drug pricing, and coverage policy, lab payment stability may seem a niche concern. However, given the central role of diagnostics in clinical care and the potential for downstream cost implications (e.g., more expensive care resulting from delayed diagnostics), Medicare lab reimbursement policy is likely to attract sustained attention.

Providers, laboratories, and advocacy groups will need to remain engaged in policy developments, assess the implications of potential rate changes, and communicate the clinical and economic value of stable, sustainable lab reimbursement. The outcomes of these debates will not only affect laboratory stakeholders but also the broader healthcare ecosystem’s ability to deliver high‑quality, cost‑effective care to Medicare beneficiaries.

Sources

1. Testing labs rally to kill Medicare pay cuts, Axios, December 10, 2025.
2. PAMA and Medicare lab payment background, CMS Fact Sheet.
3. PAMA and SALSA overview, American Society for Clinical Pathology analysis.
4. Reforming the Medicare Clinical Laboratory Fee Schedule, The RESULTS Act, policy brief.
5. Coalition Urges Congress to Pass Medicare Lab Fee Schedule Reform, Clinical Lab Products.
6. ADLM endorsement of the RESULTS Act.
7. Medicare lab reimbursement dynamics and cut impact.
8. Capstone analysis of potential delay and financial impacts.
9. Historical delays and implementation timeline for PAMA reductions.